{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:15:53Z","timestamp":1790237753860,"version":"4.1.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T00:00:00Z","timestamp":1695600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Lung adenocarcinoma (LUAD) is the major subtype of lung cancer and has a poor prognosis. Disulfidptosis is a novel regulated cell death form characterized by aberrant disulfide stress and actin network collapse. This study aimed to identify disulfidptosis-related lncRNAs, and predict LUAD patients\u2019 prognosis and response to antitumor therapies by establishing a disulfidptosis-related lncRNA model.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Transcriptome and clinical data of LUAD patients were obtained from the TCGA database. Pearson correlation and Cox regression analysis was used to identify disulfidptosis-related lncRNAs associated with overall survival. LASSO regression analysis was adopted to construct the prognostic model. GO, KEGG and GSEA analysis was used to identify cellular pathways related to this model. Immune cell infiltration was investigated by ESTIMATE and CIBERSORT algorithms. Tumor mutational burden (TMB) and its association with model-derived risk score were analyzed using simple nucleotide variation data. Patients\u2019 response to immunotherapy and other antineoplastic drugs was predicted by the TIDE algorithm and GDSC tool, respectively.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> We identified 127 disulfidptosis-related lncRNAs, and a prognostic model that consists eight of them (KTN1-AS1, AL365181.3, MANCR, LINC01352, AC090559.1, AC093673.1, AP001094.3, and MHENCR) was established and verified. The prognostic model could stratify LUAD patients into two distinct risk-score groups. A high risk score was an independent prognosis factor indicating poor overall survival, and correlated with reduced immune cell infiltration, high TMB, and lower activity of tumor immune response. Immune checkpoint blockade might bring more survival benefits to the high-risk LUAD patients, whereas low-risk patients might be more responsive to targeted therapy and diverse kinase inhibitors.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> We established a disulfidptosis-related lncRNA model that can be exploited to predict the prognosis, tumor mutational burden, immune cell infiltration landscape, and response to immunotherapy and targeted therapy in LUAD patients.<\/jats:p>","DOI":"10.3389\/fphar.2023.1254119","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T04:44:37Z","timestamp":1695703477000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["A disulfidptosis-related lncRNA prognostic model to predict survival and response to immunotherapy in lung adenocarcinoma"],"prefix":"10.3389","volume":"14","author":[{"given":"Hai-Bo","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Yan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1016\/j.celrep.2019.02.059","article-title":"lncRNA KHPS1 activates a poised enhancer by triplex-dependent recruitment of epigenomic regulators","volume":"26","author":"Blank-Giwojna","year":"2019","journal-title":"Cell. Rep."},{"key":"B2","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4939-7493-1_12","article-title":"Profiling tumor infiltrating immune cells with CIBERSORT","volume":"1711","author":"Chen","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1198878","DOI":"10.3389\/fimmu.2023.1198878","article-title":"Leveraging a disulfidptosis-based signature to improve the survival and drug sensitivity of bladder cancer patients","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.3390\/cells8091015","article-title":"Long non-coding RNA in the pathogenesis of cancers","volume":"8","author":"Chi","year":"2019","journal-title":"Cells"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-16-2554","article-title":"Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma","volume":"23","author":"Dong","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/08916934.2021.1913582","article-title":"SChLAP1 contributes to non-small cell lung cancer cell progression and immune evasion through regulating the AUF1\/PD-L1 axis","volume":"54","author":"Du","year":"2021","journal-title":"Autoimmunity"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","article-title":"Non-small cell lung cancer: Epidemiology, screening, diagnosis, and treatment","volume":"94","author":"Duma","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"B8","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/s41419-020-03198-y","article-title":"Novel lncRNA UPLA1 mediates tumorigenesis and prognosis in lung adenocarcinoma","volume":"11","author":"Han","year":"2020","journal-title":"Cell. Death Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: New dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.3892\/ol.2019.10095","article-title":"Stromal tumor-infiltrating lymphocytes evaluated on H&E-stained slides are an independent prognostic factor in epithelial ovarian cancer and ovarian serous carcinoma","volume":"17","author":"Hwang","year":"2019","journal-title":"Oncol. Lett."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"12226","DOI":"10.18632\/oncotarget.24203","article-title":"MUC16 overexpression induced by gene mutations promotes lung cancer cell growth and invasion","volume":"9","author":"Kanwal","year":"2018","journal-title":"Oncotarget"},{"key":"B14","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.ccell.2015.02.004","article-title":"A cytoplasmic NF-\u03baB interacting long noncoding RNA blocks I\u03baB phosphorylation and suppresses breast cancer metastasis","volume":"27","author":"Liu","year":"2015","journal-title":"Cancer Cell."},{"key":"B15","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41556-023-01091-2","article-title":"Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis","volume":"25","author":"Liu","year":"2023","journal-title":"Nat. Cell. Biol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"bbab260","DOI":"10.1093\/bib\/bbab260","article-title":"oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data","volume":"22","author":"Maeser","year":"2021","journal-title":"Brief. Bioinform"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1016\/j.annonc.2020.08.2105","article-title":"KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden","volume":"31","author":"Marinelli","year":"2020","journal-title":"Ann. Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41525-019-0107-6","article-title":"Spontaneous mutations in the single TTN gene represent high tumor mutation burden","volume":"5","author":"Oh","year":"2020","journal-title":"NPJ Genom Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/s41423-020-00565-9","article-title":"Tumor-infiltrating lymphocytes in the immunotherapy era","volume":"18","author":"Paijens","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/s41392-022-01110-y","article-title":"Regulated cell death (RCD) in cancer: Key pathways and targeted therapies","volume":"7","author":"Peng","year":"2022","journal-title":"Signal Transduct. Target Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jtho.2021.10.013","article-title":"Diminished efficacy of programmed death-(ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status","volume":"17","author":"Ricciuti","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"B23","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1001\/jamaoncol.2015.0830","article-title":"Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: A secondary analysis of the NeoALTTO trial","volume":"1","author":"Salgado","year":"2015","journal-title":"JAMA Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.annonc.2022.12.002","article-title":"Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma","volume":"34","author":"Scalera","year":"2023","journal-title":"Ann. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1158\/2159-8290.CD-20-0522","article-title":"Tumor mutational burden as a predictive biomarker in solid tumors","volume":"10","author":"Sha","year":"2020","journal-title":"Cancer Discov."},{"key":"B26","doi-asserted-by":"publisher","first-page":"13341","DOI":"10.1038\/s41598-019-49710-z","article-title":"A novel digital score for abundance of tumour infiltrating lymphocytes predicts disease free survival in oral squamous cell carcinoma","volume":"9","author":"Shaban","year":"2019","journal-title":"Sci. Rep."},{"key":"B27","doi-asserted-by":"publisher","first-page":"469","DOI":"10.5858\/arpa.2014-0128-RA","article-title":"Biomarkers in lung adenocarcinoma: A decade of progress","volume":"139","author":"Sholl","year":"2015","journal-title":"Arch. Pathol. Lab. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41580-020-00315-9","article-title":"Gene regulation by long non-coding RNAs and its biological functions","volume":"22","author":"Statello","year":"2021","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1158\/2159-8290.CD-20-1274","article-title":"Nongenetic evolution drives lung adenocarcinoma spatial heterogeneity and progression","volume":"11","author":"Tavernari","year":"2021","journal-title":"Cancer Discov."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1634\/theoncologist.2015-0084","article-title":"Targeting the KRAS pathway in non-small cell lung cancer","volume":"21","author":"Tomasini","year":"2016","journal-title":"Oncologist"},{"key":"B32","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41576-018-0017-y","article-title":"Towards a complete map of the human long non-coding RNA transcriptome","volume":"19","author":"Uszczynska-Ratajczak","year":"2018","journal-title":"Nat. Rev. Genet."},{"key":"B33","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41423-018-0027-x","article-title":"Tumor-infiltrating B cells: Their role and application in anti-tumor immunity in lung cancer","volume":"16","author":"Wang","year":"","journal-title":"Cell. Mol. Immunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"110368","DOI":"10.1016\/j.intimp.2023.110368","article-title":"Disulfidptosis classification of hepatocellular carcinoma reveals correlation with clinical prognosis and immune profile","volume":"120","author":"Wang","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-019-1170-y","article-title":"CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy","volume":"569","author":"Wang","year":"","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.omtn.2019.08.005","article-title":"Long non-coding RNA LINC00628 interacts epigenetically with the LAMA3 promoter and contributes to lung adenocarcinoma","volume":"18","author":"Xu","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B37","doi-asserted-by":"publisher","first-page":"9787","DOI":"10.1007\/s00432-023-04877-x","article-title":"Based on disulfidptosis, revealing the prognostic and immunological characteristics of renal cell carcinoma with tumor thrombus of vena cava and identifying potential therapeutic target AJAP1","volume":"149","author":"Yang","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat. Commun."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1016\/j.jtho.2019.07.031","article-title":"Genomic landscape and immune microenvironment features of preinvasive and early invasive lung adenocarcinoma","volume":"14","author":"Zhang","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1180404","DOI":"10.3389\/fendo.2023.1180404","article-title":"Crosstalk of disulfidptosis-related subtypes, establishment of a prognostic signature and immune infiltration characteristics in bladder cancer based on a machine learning survival framework","volume":"14","author":"Zhao","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)."},{"key":"B41","doi-asserted-by":"publisher","first-page":"115616","DOI":"10.1016\/j.bcp.2023.115616","article-title":"eIF3a sustains non-small cell lung cancer stem cell-like properties by promoting YY1-mediated transcriptional activation of beta-catenin","volume":"213","author":"Zheng","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"6973","DOI":"10.1073\/pnas.1221609110","article-title":"T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy","volume":"110","author":"Zhong","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B43","doi-asserted-by":"publisher","first-page":"21597","DOI":"10.18632\/aging.103952","article-title":"Construction and validation of an immunity-related prognostic signature for breast cancer","volume":"12","author":"Zhu","year":"2020","journal-title":"Aging (Albany NY)"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1254119\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T04:44:41Z","timestamp":1695703481000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1254119\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,25]]},"references-count":43,"alternative-id":["10.3389\/fphar.2023.1254119"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1254119","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,25]]},"article-number":"1254119"}}